Semaglutide and cardiovascular outcomes in obesity without diabetes
New England Journal of Medicine
2023
Study summary
SELECT evaluated semaglutide for cardiovascular event reduction in adults with overweight or obesity without diabetes.
Peptides studied
Goals studied
Stack studied
Metabolic Stack
Key findings
Semaglutide reduced major adverse cardiovascular events in this population.
Study details
Study type
randomized clinical trial
Journal
New England Journal of Medicine
DOI / PubMed
10.1056/NEJMoa2307563
Year
2023
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.
